Use: Labeled indications
- Unresectable hepatocellular carcinoma
- Advanced renal cell carcinoma
- Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment
Full indications and usage US FDA label
1 INDICATIONS AND USAGE NEXAVAR is a kinase inhibitor indicated for the treatment of
- Unresectable hepatocellular carcinoma (1.1)
- Advanced renal cell carcinoma (1.2)
- Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma NEXAVAR ® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
Contraindications
4 CONTRAINDICATIONS • NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions (5.8)]. • NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. (4) • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. (4)
US FDA labelDosing: Adult
The recommended dosage is 400 mg orally twice daily without food. (2.1)
2.1 Recommended Dosage
2.1 Recommended Dosage The recommended dosage of NEXAVAR is 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity.
2.2 Dosage Modifications for Adverse Reactions Recommended
2.2 Dosage Modifications for Adverse Reactions Recommended Dosage Modifications The recommended dosage modifications for adverse reactions are provided in Tables 1, 2, and 3. Table 1: Recommended Dose Reductions for Adverse Reactions Dose Reduction Hepatocellular Carcinoma and Renal Cell Carcinoma Differentiated Thyroid Carcinoma First Dose Reduction 400 mg orally once daily 400 mg orally in the morning and 200 mg orally in the evening about 12 hours apart OR 200 mg orally in the morning and 400 mg orally in the evening about 12 hours apart Second Dose Reduction 200 mg orally once daily OR 400 every other day 200 mg orally twice daily Third Dose Reduction None 200 mg orally once daily Table 2: Recommended Dosage Modifications of NEXAVAR for Adverse Reactions Adverse Reaction Severity 1 NEXAVAR Dosage Modification Cardiovascular Events [see Warnings and Precautions (5.1)] Cardiac Ischemia and/or Infarction Grade 2 and above Permanently discontinue.
Congestive Heart Failure Grade 3 Interrupt 2 until Grade 1 or less, resume at reduced dose by 1 dose level. 3 Grade 4 Permanently discontinue. Hemorrhage [see Warnings and Precautions (5.2)] Grade 2 and above requiring medical intervention Permanently discontinue. Hypertension [see Warnings and Precautions (5.3)] Grade 2 (symptomatic/persistent) OR Grade 2 symptomatic increase by greater than 20 mm Hg (diastolic) or greater than 140/90 mm Hg if previously within normal limits OR Grade 3 Interrupt until symptoms resolve and diastolic blood pressure less than 90 mm Hg, then resume at reduced dose by 1 dose level. 3 If needed, reduce another dose level. 3 Grade 4 Permanently discontinue.
Gastrointestinal Perforation [see Warnings and Precautions (5.5)] Any grade Permanently discontinue. QT Interval Prolongation [see Warnings and Precautions (5.9)] Greater than 500 milliseconds OR Increase from baseline of 60 milliseconds or greater Interrupt and correct electrolyte abnormalities (magnesium, potassium, calcium).
Use medical judgement before restarting. Drug-Induced Liver Injury [see Warnings and Precautions (5.10)] Grade 3 ALT or higher in the absence of another cause 4 OR AST/ALT greater than 3 × upper limit normal (ULN) with bilirubin greater than 2 × ULN in the absence of another cause 4 Permanently discontinue. Non-hematological toxicities [see Adverse Reactions (6.1)] Grade 2 Continue treatment at reduced dose by 1 dose level.
Grade 3 1 st occurrence Interrupt until Grade 2 or less, then resume at reduced dose by 1 dose level. No improvement within 7 days OR 2 nd or 3 rd occurrence Interrupt until Grade 2 or less, then resume at reduced dose by 2 dose levels. 4 th occurrence Interrupt until Grade 2 or less, then resume at reduced dose by 2 dose levels for HCC and RCC or 3 dose levels for DTC.
Grade 4 Permanently discontinue. 1 Adverse reactions graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0). 2 If no recovery after 30 day interruption, discontinue treatment unless the patient is deriving clinical benefit. 3 If more than 2 dose reductions are required, permanently discontinue treatment. 4 In addition, any grade increased alkaline phosphatase in the absence of known bone pathology and Grade 2 or worse increased bilirubin; any 1 of the following: INR of 1.5 or greater, ascites and/or encephalopathy in the absence of underlying cirrhosis or other organ failure considered to be due to drug-induced liver injury. Table 3: Recommended Dosage Modifications for Dermatologic Toxicities Dermatologic Toxicity Grade Occurrence NEXAVAR Dosage Modification Hepatocellular and Renal Cell Carcinoma Differentiated Thyroid Carcinoma Grade 2: Painful erythema and swelling of the hands or feet and/or discomfort affecting the patient’s normal activities 1 st occurrence Continue NEXAVAR and consider topical therapy for symptomatic relief.
If no improvement within 7 days, see below. Decrease NEXAVAR to 600 mg daily. If no improvement within 7 days, see below. No improvement within 7 days at reduced dose OR 2 nd and 3 rd occurrence Interrupt NEXAVAR until resolved or improved to Grade 0 to 1. Interrupt NEXAVAR until completely resolved or improved to Grade1. When resuming treatment, decrease dose by 1 dose level.
When resuming treatment, decrease dose by 1 dose level for 2 nd occurrence and 2 doses levels for 3 rd occurrence. 4 th occurrence Discontinue NEXAVAR treatment. Grade 3: Moist desquamation, ulceration, blistering, or severe pain of the hands or feet, resulting in inability to work or perform activities of daily living 1 st occurrence Interrupt NEXAVAR until resolved or improved to Grade 0 to 1 Interrupt NEXAVAR until completely resolved or improved to Grade 1.
When resuming treatment, decrease dose by 1 dose level. When resuming treatment, decrease dose by 1 dose level. 2 nd occurrence Interrupt NEXAVAR until resolved or improved to Grade 0 to 1 Interrupt NEXAVAR until completely resolved or improved to Grade 1. When resuming treatment, decrease dose by 1 dose level. When resuming treatment, decrease dose by 2 dose levels. 3 rd occurrence Discontinue NEXAVAR treatment.
Following improvement of Grade 2 or 3 dermatologic toxicity to Grade 0 or 1 for at least 28 days on a reduced dose of NEXAVAR, the dose of NEXAVAR may be increased 1 dose level from the reduced dose. Approximately 50% of patients requiring a dose reduction for dermatologic toxicity are expected to meet these criteria for resumption of the higher dose and roughly 50% of patients resuming the previous dose are expected to tolerate the higher dose (that is, maintain the higher dose level without recurrent Grade 2 or higher dermatologic toxicity).
Dosing: Altered kidney function
8.6 Renal Impairment No dose adjustment is necessary for patients with mild, moderate or severe renal impairment who are not on dialysis. The pharmacokinetics of sorafenib have not been studied in patients who are on dialysis [see Clinical Pharmacology (12.3)].
Patients with Renal Impairment Mild (CLcr 50-80 mL/min), moderate (CLcr 30 - <50 mL/min), and severe (CLcr <30 mL/min) renal impairment do not affect the pharmacokinetics of sorafenib [see Use in Specific Populations (8.6)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The pharmacokinetics of sorafenib have not been studied in patients with severe (Child-Pugh C) hepatic impairment [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of NEXAVAR have not been established in pediatric patients. Juvenile Animal Toxicity Data Repeat dosing of sorafenib to young and growing dogs resulted in irregular thickening of the femoral growth plate at daily sorafenib doses ≥600 mg/m 2 (approximately 0.3 times the AUC at the recommended human dose), hypocellularity of the bone marrow adjoining the growth plate at 200 mg/m 2 /day (approximately 0.1 times the AUC at the recommended human dose), and alterations of the dentin composition at 600 mg/m 2 /day.
Similar effects were not observed in adult dogs when dosed for 4 weeks or less.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In total, 59% of HCC patients treated with NEXAVAR were age 65 years or older and 19% were 75 and older. In total, 32% of RCC patients treated with NEXAVAR were age 65 years or older and 4% were 75 and older. No differences in safety or efficacy were observed between older and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Dosage forms
Philippines
- Film-coated tablet: 200 mg
Registered products in the Philippines
9 products registered with the Food and Drug Administration (FDA) Philippines list Sorafenib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products9
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlvofenibSorafenib (as tosylate) | 200 mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | PharOS MT Ltd..Malta | Metro Drug, Inc..Trader: Lotus International Pte. Limited | DR-XY49127 | Jul 9, 2029 | |
BinefarosSorafenib (as Tosylate) | 200 mg Film-Coated TabletHDPE Bottle x 30’s and 120’s (Box of 1 Bottle) | RxVAT-exempt | BDR Pharmaceuticals International Pvt. Ltd. – Oncology UnitIndia | OEP Philippines, Inc.Importer: Ambica International Corporation | DRP-14044-01 | Jun 8, 2028 | |
LivonibeSorafenib Tosylate | 200 mg Film-Coated TabletHDPE Bottle x 30's and 120's (Box of 1 Bottle) | RxVAT-exempt | BDR Pharmaceuticals International Pvt. Ltd. - Oncology UnitIndia | Ambica International Corporation | DRP-14044 | Jun 8, 2028 | |
NexavarSorafenib (as Tosylate) | 200 mg Film-Coated TabletPP/Alu/Alu Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Bayer AGGermany | Importer: Bayer Philippines, Inc. | DR-XY32442 | Dec 7, 2030 | |
Nexavex-200Sorafenib (as tosylate) | 200 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentine | VE Pharma Inc.Trader: Vexxa Lifesciences FZE | DR-XY49669 | Mar 11, 2031 | |
OnconibSorafenib (as tosylate) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14682 | Nov 22, 2028 | |
OnconibSorafenib (as tosylate) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15344 | Jun 25, 2029 | |
SoragetSorafenib | 200 mg Film Coated TabletHDPE Plastic Bottle x 30's, 60's, 120's (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-17292 | Nov 12, 2030 | |
Soravar 200Sorafenib (as tosilate) | 200mg Film Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Importer: Accord Healthcare Limited-Philippine Branch Office | DR-XY48773 | Jun 13, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: • 200 mg sorafenib, round, biconvex, red film-coated tablets, debossed with the “Bayer cross” on one side and “200” on the other side. • 200 mg sorafenib, round, faceted biconvex, red film-coated tablets, debossed with the “Bayer cross” on one side and “200” on the other side. Tablets: 200 mg (3)
Warnings/Precautions
- • Cardiovascular Events: Consider temporary or permanent discontinuation of NEXAVAR. (2.2, 5.1)
- • Hemorrhage: Discontinue NEXAVAR if needed. (5.2)
- • Hypertension: Monitor blood pressure weekly during the first 6 weeks and periodically thereafter. Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (5.3)
- • Dermatologic Toxicities: Interrupt and/or decrease dose. Discontinue for severe or persistent reactions, or if Stevens-Johnson syndrome and toxic epidermal necrolysis is suspected. (5.4)
- • Gastrointestinal Perforation: Discontinue NEXAVAR. (5.5)
- • Risk of Impaired Wound Healing: Withhold NEXAVAR for at least 10 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of NEXAVAR after resolution of wound healing complications has not been established. (5.7)
- • QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias. Correct electrolytes. Interrupt if QTc greater than 500 msec or increases greater than 60 msec from baseline. (2.2, 5.9, 12.2)
- • Drug-Induced Liver Injury: Monitor liver function tests regularly; discontinue for unexplained transaminase elevations. (5.10)
- • Embryo-Fetal Toxicity: NEXAVAR may cause fetal harm. Advise …
5.1 Cardiovascular Events
5.1 Cardiovascular Events In the SHARP (HCC) study, the incidence of cardiac ischemia/infarction was 2.7% in NEXAVAR-treated patients compared with 1.3% in those receiving placebo; in the TARGET (RCC) study, the incidence of cardiac ischemia/infarction was higher in the NEXAVAR-treated group (2.9%) compared with patients receiving placebo (0.4%), and in the DECISION (DTC) study, the incidence of cardiac ischemia/infarction was 1.9% in the NEXAVAR-treated group compared with 0% in patients receiving placebo. Patients with unstable coronary artery disease or recent myocardial infarction were excluded from this study.
In multiple clinical trials, congestive heart failure has been reported in 1.9% of NEXAVAR-treated patients (N=2276) [see Adverse Reactions (6.2)]. Consider temporary or permanent discontinuation of NEXAVAR in patients who develop cardiovascular events [see Dosage and Administration (2.2)].
5.2 Hemorrhage
5.2 Hemorrhage An increased risk of bleeding may occur following NEXAVAR administration. In the SHARP (HCC) study, the rates of bleeding from esophageal varices (2.4% and 4%) and of bleeding with a fatal outcome from any site (2.4% and 4%) were similar in NEXAVAR-treated patients and those receiving placebo, respectively.
In the TARGET (RCC) study, bleeding was reported in 15.3% of patients in the NEXAVAR-treated group and 8.2% of patients receiving placebo. The incidence of Grade 3 and 4 bleeding was 2% and 0%, respectively, in NEXAVAR-treated patients, and 1.3% and 0.2%, respectively, in those receiving placebo. There was one fatal hemorrhage in each treatment group in the TARGET (RCC) study.
In the DECISION (DTC) study, bleeding was reported in 17.4% of NEXAVAR-treated patients and 9.6% of those receiving placebo; however, the incidence of Grade 3 bleeding was similar (1% and 1.4%) in NEXAVAR-treated patients and in those receiving placebo. If any bleeding necessitates medical intervention, consider permanent discontinuation of NEXAVAR [see Dosage and Administration (2.2)].
Due to the potential risk of bleeding, treat tracheal, bronchial, and esophageal infiltration with local therapy prior to administering NEXAVAR in patients with DTC.
5.3 Hypertension In
5.3 Hypertension In the SHARP (HCC) study, hypertension was reported in 9.4% of NEXAVAR-treated patients and 4.3% of patients receiving placebo. In the TARGET (RCC) study, hypertension was reported in 16.9% of NEXAVAR-treated patients and 1.8% of patients receiving placebo. In the DECISION (DTC) study, hypertension was reported in 40.6% of NEXAVAR-treated patients and 12.4% of patients receiving placebo.
Hypertension was usually mild to moderate, occurred early in the course of treatment, and was managed with standard antihypertensive therapy. Permanent discontinuation due to hypertension occurred in 1 of 297 NEXAVAR-treated patients in the SHARP (HCC) study, 1 of 451 NEXAVAR-treated patients in the TARGET (RCC) study, and 1 of 207 NEXAVAR-treated patients in the DECISION (DTC) study.
Monitor blood pressure weekly during the first 6 weeks of NEXAVAR. Thereafter, monitor blood pressure and treat hypertension, if required, in accordance with standard medical practice. In cases of severe or persistent hypertension despite institution of antihypertensive therapy, consider temporary or permanent discontinuation of NEXAVAR [see Dosage and Administration (2.2)].
5.4 Dermatologic Toxicities
5.4 Dermatologic Toxicities Hand-foot skin reaction and rash represent the most common adverse reactions attributed to NEXAVAR. Rash and hand-foot skin reaction are usually Grade 1 and 2 and generally appear during the first six weeks of treatment with NEXAVAR. Permanent discontinuation of therapy due to hand-foot skin reaction occurred in 4 (1.3%) of 297 NEXAVAR-treated patients with HCC, 3 (0.7%) of 451 NEXAVAR-treated patients with RCC, and 11 (5.3%) of 207 NEXAVAR-treated patients with DTC.
Management of dermatologic toxicities may include topical therapies for symptomatic relief, temporary treatment interruption and/or dose reduction of NEXAVAR, or in severe or persistent cases, permanent discontinuation of NEXAVAR [see Dosage and Administration (2.2)]. There have been reports of severe dermatologic toxicities, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
These cases may be life-threatening. Discontinue NEXAVAR if SJS or TEN are suspected.
5.5 Gastrointestinal Perforation
5.5 Gastrointestinal Perforation Gastrointestinal perforation has been reported in less than 1% of patients taking NEXAVAR. In some cases this was not associated with apparent intra-abdominal tumor. In the event of a gastrointestinal perforation, permanently discontinue NEXAVAR.
5.6 Increased Risk of Bleeding with Concomitant Use of Warfarin
5.6 Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. Monitor patients taking concomitant warfarin regularly for changes in prothrombin time (PT), INR or clinical bleeding episodes.
5.7 Risk of Impaired Wound Healing
5.7 Risk of Impaired Wound Healing Impaired wound healing can occur in patients who receive drugs that inhibit the VEGF signaling pathway. Therefore, NEXAVAR has the potential to adversely affect wound healing. Withhold NEXAVAR for at least 10 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing.
The safety of resumption of NEXAVAR after resolution of wound healing complications has not been established.
5.8 Increased Mortality Observed
5.8 Increased Mortality Observed with NEXAVAR Administered in Combination with Carboplatin/Paclitaxel and Gemcitabine/Cisplatin in Squamous Cell Lung Cancer In a subset analysis of two randomized controlled trials in chemo-naive patients with Stage IIIB-IV non-small cell lung cancer, patients with squamous cell carcinoma experienced higher mortality with the addition of NEXAVAR compared to those treated with carboplatin/paclitaxel alone (HR 1.81; 95% CI 1.19, 2.74) and gemcitabine/cisplatin alone (HR 1.22; 95% CI 0.82, 1.80). The use of NEXAVAR in combination with carboplatin/paclitaxel is contraindicated in patients with squamous cell lung cancer.
NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. The safety and effectiveness of NEXAVAR has not been established in patients with non-small cell lung cancer.
5.9 QT Interval Prolongation
5.9 QT Interval Prolongation NEXAVAR can prolong the QT/QTc interval. QT/QTc interval prolongation increases the risk for ventricular arrhythmias. Avoid NEXAVAR in patients with congenital long QT syndrome. Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics.
Correct electrolyte abnormalities (magnesium, potassium, calcium). Interrupt NEXAVAR if QTc interval is greater than 500 milliseconds or for an increase from baseline of 60 milliseconds or greater [see Clinical Pharmacology (12.2)].
5.10 Drug-Induced Liver Injury
5.10 Drug-Induced Liver Injury Sorafenib-induced hepatitis is characterized by a hepatocellular pattern of liver damage with significant increases of transaminases which may result in hepatic failure and death. Increases in bilirubin and INR may also occur. The incidence of severe drug-induced liver injury, defined as elevated transaminase levels above 20 times the upper limit of normal or transaminase elevations with significant clinical sequelae (for example, elevated INR, ascites, fatal, or transplantation), was two of 3,357 patients (0.06%) in a global monotherapy database.
Monitor liver function tests regularly. In case of significantly increased transaminases without alternative explanation, such as viral hepatitis or progressing underlying malignancy, discontinue NEXAVAR [see Dosage and Administration (2.2)].
5.11 Embryo-Fetal Toxicity
5.11 Embryo-Fetal Toxicity Based on its mechanism of action and findings in animals, NEXAVAR may cause fetal harm when administered to a pregnant woman. Sorafenib caused embryo-fetal toxicities in animals at maternal exposures that were significantly lower than the human exposures at the recommended dose of 400 mg twice daily.
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of NEXAVAR. Advise male patients with female partners of reproductive potential and pregnant partners to use effective contraception during treatment and for 3 months following the last dose of NEXAVAR [see Use in Specific Populations (8.1, 8.3)].
5.12 Impairment of Thyroid Stimulating Hormone Suppression in Differentiated
5.12 Impairment of Thyroid Stimulating Hormone Suppression in Differentiated Thyroid Carcinoma NEXAVAR impairs exogenous thyroid suppression. In the DECISION (DTC) study, 99% of patients had a baseline thyroid stimulating hormone (TSH) level less than 0.5 mU/L. Elevation of TSH level above 0.5 mU/L was observed in 41% of NEXAVAR-treated patients as compared with 16% of those receiving placebo patients.
For patients with impaired TSH suppression while receiving NEXAVAR, the median maximal TSH was 1.6 mU/L and 25% had TSH levels greater than 4.4 mU/L. Monitor TSH levels monthly and adjust thyroid replacement medication as needed in patients with DTC.
Drug interactions
- Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (7.1)
7.1 Effect of Other Drugs
7.1 Effect of Other Drugs on NEXAVAR Strong CYP3A4 Inducers The concomitant use of NEXAVAR with rifampin, a strong CYP3A4 inducer decreased the mean AUC of sorafenib, which may decrease the antitumor activity [see Clinical Pharmacology (12.3)]. Avoid concomitant use of NEXAVAR with strong CYP3A4 inducers, when possible, because these drugs can decrease the systemic exposure to sorafenib.
Neomycin The concomitant use of NEXAVAR with neomycin decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use of NEXAVAR with neomycin. The effects of other antibiotics on the pharmacokinetics of sorafenib have not been studied [see Clinical Pharmacology (12.3)].
7.2 Concomitant Use of Warfarin
7.2 Concomitant Use of Warfarin The concomitant use of NEXAVAR and warfarin may increase the risk of bleeding or increased the INR. Monitor INR and for clinical bleeding episodes in patients taking warfarin while receiving NEXAVAR [see Warnings and Precautions (5.6)].
7.3 Drugs That Prolong the QT Interval
7.3 Drugs That Prolong the QT Interval NEXAVAR is associated with QTc interval prolongation. Avoid coadministration of NEXAVAR with medicinal products with a known potential to prolong QT/QTc interval [see Warnings and Precautions (5.9), Clinical Pharmacology (12.2)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Sorafenib undergoes oxidative metabolism by hepatic CYP3A4, as well as glucuronidation by UGT1A9.
Drug Interactions Studies Effect of Strong CYP3A4 Inhibitors on Sorafenib : Ketoconazole, a strong inhibitor of CYP3A4 and P-glycoprotein, administered at a dose of 400 not alter the mean AUC of a single oral dose of NEXAVAR 50 mg in healthy subjects.
Effect of Strong CYP3A4 Inducers on Sorafenib : Concomitant use of NEXAVAR with rifampin administered at a dose of 600 mg once daily for 5 days with a single oral dose of NEXAVAR 400 mg in healthy volunteers resulted in a 37% decrease in the mean AUC of sorafenib.
Effect of Sorafenib on Other Drugs: NEXAVAR 400 mg twice daily for 28 days did not increase the systemic exposure of concomitantly administered midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), and omeprazole (CYP2C19 substrate) [see Clinical Pharmacology ( 12.3 )].
In Vitro Studies Sorafenib competitively inhibited CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in vitro.
However, NEXAVAR 400 mg twice daily for 28 days with substrates of CYP3A4, CYP2D6 and CYP2C19 did not increase the systemic exposure of these substrates [see Drug Interactions ( 7.3 )].
Sorafenib did not increase CYP1A2 and CYP3A4 activities, suggesting that sorafenib is unlikely to induce CYP1A2 or CYP3A4 in humans.
Sorafenib inhibits glucuronidation by UGT1A1 and UGT1A9 in vitro.
Adverse reactions
- The following clinically significant adverse reactions are discussed elsewhere in the labeling: • Cardiovascular events [see Warnings and Precautions (5.1)] • Hemorrhage [see Warnings and Precautions (5.2)] • Hypertension [see Warnings and Precautions (5.3)] • Dermatologic toxicities [see Warnings and Precautions (5.4)] • Gastrointestinal perforation [see Warnings and Precautions (5.5)] • QT interval prolongation [see Warnings and Precautions (5.9)
- and Clinical Pharmacology (12.2)] • Drug-induced liver injury [see Warnings and Precautions (5.10)] • Impairment of TSH suppression in DTC [see Warnings and Precautions (5.12)] The most common adverse reactions (≥20%) are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage. (6) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described reflect exposure to NEXAVAR in 955 patients who participated in placebo-controlled studies in hepatocellular carcinoma (N=297), advanced renal cell carcinoma (N=451), or differentiated thyroid carcinoma (N = 207).
The most common adverse reactions (≥20%), which were considered to be related to NEXAVAR, in patients with HCC, RCC or DTC are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage. Hepatocellular Carcinoma Table 4 shows the percentage of patients in the SHARP (HCC) study experiencing adverse reactions that were reported in at least 10% of patients and at a higher rate in the NEXAVAR-treated group than in those receiving placebo.
Table 4: Adverse Reactions Reported in at Least 10% of Patients and at a Higher Rate in NEXAVAR Arm than the Placebo Arm – SHARP (HCC) Adverse Reaction 1 NEXAVAR N=297 Placebo N=302 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Any Adverse Reaction 98 39 6 96 24 8 Gastrointestinal Diarrhea 55 10 <1 25 2 0 Anorexia 29 3 0 18 3 <1 Nausea 24 1 0 20 3 0 Vomiting 15 2 0 11 2 0 Constipation 14 0 0 10 0 0 Constitutional symptoms Fatigue 46 9 1 45 12 2 Weight loss 30 2 0 10 1 0 Pain Pain, abdomen 31 9 0 26 5 1 Dermatology/skin Hand-foot skin reaction 21 8 0 3 <1 0 Rash/desquamation 19 1 0 14 0 0 Alopecia 14 0 0 2 0 0 Pruritus 14 <1 0 11 <1 0 Dry skin 10 0 0 6 0 0 Hepatobiliary/pancreas Liver dysfunction 11 2 1 8 2 1 1 Adverse reactions graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0). Hypertension was reported in 9% of patients treated with NEXAVAR and 4% of those receiving placebo.
Grade 3 hypertension was reported in 4% of NEXAVAR-treated patients and 1% of those receiving placebo. Hemorrhage/bleeding was reported in 18% of those receiving NEXAVAR and 20% of patients receiving placebo. The rates of Grade 3 and 4 bleeding were also higher in patients receiving placebo (Grade 3 – 3% NEXAVAR and 5% placebo and Grade 4 – 2% NEXAVAR and 4% placebo).
Bleeding from esophageal varices was reported in 2.4% in NEXAVAR-treated patients and 4% of patients receiving placebo. Renal failure was reported in <1% of patients treated with NEXAVAR and 3% of patients receiving placebo. Clinical pancreatitis was reported in 1 of 297 NEXAVAR-treated patients (Grade 2). The rate of adverse reactions (including those associated with progressive disease) resulting in permanent discontinuation was similar in both the NEXAVAR-treated patients and those receiving placebo (32% of NEXAVAR-treated patients and 35% of patients receiving placebo).
Laboratory test abnormalities reported in SHARP are presented in Table 5. Table 5: Laboratory Test Abnormalities Reported in SHARP (HCC) Laboratory Parameter 1 NEXAVAR N=297 Placebo N=302 All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hypoalbuminemia 59 0 47 0 Elevated Lipase 40 9 37 9 Lymphopenia 47 NR 42 NR Thrombocytopenia 46 4 41 <1 Elevated INR 42 4 34 2 Hypophosphatemia 35 11 11 2 Elevated Amylase 34 2 29 2 Hypocalcemia 27 2.4 15 1 Hypokalemia 10 <1 6 <1 1- Laboratory parameters graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0).
NR = not reported Renal Cell Carcinoma Table 6 shows the percentage of patients in the TARGET (RCC) study experiencing adverse reactions that were reported in at least 10% of patients and at a higher rate in NEXAVAR-treated patients arm than in those receiving placebo. The rate of adverse reactions (including those associated with progressive disease) resulting in permanent discontinuation was similar in both the NEXAVAR-treated patients and patients receiving placebo (10% and 8%, respectively).
Clinical pancreatitis was reported in 3 of 451 NEXAVAR-treated patients (one Grade 2 and two Grade 4). Table 6: Adverse Reactions Reported in at Least 10% of Patients and at a Higher Rate in NEXAVAR Arm than the Placebo Arm – TARGET (RCC) Adverse Reaction 1 NEXAVAR N=451 Placebo N=451 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Any Adverse Reactions 95 31 7 86 22 6 Gastrointestinal symptoms Diarrhea 43 2 0 13 <1 0 Nausea 23 <1 0 19 <1 0 Anorexia 16 <1 0 13 1 0 Vomiting 16 <1 0 12 1 0 Constipation 15 <1 0 11 <1 0 Dermatology/skin Rash/desquamation 40 <1 0 16 <1 0 Hand-foot skin reaction 30 6 0 7 0 0 Alopecia 27 <1 0 3 0 0 Pruritus 19 <1 0 6 0 0 Dry skin 11 0 0 4 0 0 Constitutional symptoms Fatigue 37 5 <1 28 3 <1 Weight loss 10 <1 0 6 0 0 Cardiovascular, General Hypertension 17 3 <1 2 <1 0 Hemorrhage/bleeding Hemorrhage – all sites 15 2 0 8 1 <1 Pulmonary Dyspnea 14 3 <1 12 2 <1 Neurology Neuropathy-sensory 13 <1 0 6 <1 0 Pain Pain, abdomen 11 2 0 9 2 0 Pain, headache 10 <1 0 6 <1 0 Pain, joint 10 2 0 6 <1 0 1 Adverse reactions graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0).
Laboratory test abnormalities reported in TARGET are presented in Table 7. Table 7: Laboratory Test Abnormalities Reported in TARGET (RCC) Laboratory Parameter 1 NEXAVAR N=451 Placebo N=451 All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hypophosphatemia 45 13 11 3 Anemia 44 2 49 4 Elevated Lipase 41 12 30 7 Elevated Amylase 30 1 23 3 Lymphopenia 23 13 13 7 Neutropenia 18 5 10 2 Thrombocytopenia 12 1 5 0 Hypocalcemia 12 2 8 <1 Hypokalemia 5 1 <1 <1 1 Laboratory parameters graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0).
Differentiated Thyroid Carcinoma The safety of NEXAVAR was evaluated in DECISION in 416 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) treatment randomized to receive 400 mg twice daily NEXAVAR (n=207) or matching placebo (n=209) until disease progression or intolerable toxicity in a double-blind trial [see Clinical Studies (14.3)]. The data described below reflect a median exposure to NEXAVAR for 46 weeks (range 0.3 to 135).
The population exposed to NEXAVAR was 50% male, and had a median age of 63 years. Dose interruptions for adverse reactions were required in 66% of patients receiving NEXAVAR and dose reductions were required in 64% of patients. Adverse reactions that resulted in treatment discontinuation were reported in 14% of NEXAVAR-treated patients compared to 1.4% of patients receiving placebo.
Table 8 shows the percentage of DTC patients experiencing adverse reactions at a higher rate in NEXAVAR-treated patients than in patients receiving placebo in the double-blind phase of the DECISION study. Grade 3 adverse reactions occurred in 53% of NEXAVAR-treated patients compared to 23% of patients receiving placebo.
Grade 4 adverse reactions occurred in 12% of NEXAVAR-treated patients compared to 7% of patients receiving placebo. Table 8: Selected Adverse Reactions Occurring at a Higher Incidence in NEXAVAR-Treated Patients [Between Arm Difference of ≥ 5% (All Grades)1 or ≥ 2% (Grades 3 and 4)] Adverse Reaction NEXAVAR N = 207 Placebo N = 209 All Grades (%) Grades 3 and 4 (%) All Grades (%) Grades 3 and 4 (%) Skin and subcutaneous tissue disorders PPES 5 69 19 8 0 Alopecia 67 0 8 0 Rash 35 5 7 0 Pruritus 20 0.5 11 0 Dry skin 13 0.5 5 0 Erythema 10 0 0.5 0 Hyperkeratosis 7 0 0 0 Gastrointestinal disorders Diarrhea 68 6 15 1 Stomatitis 3 24 2 3 0 Nausea 21 0 12 0 Abdominal pain 2 20 1 7 1 Constipation 16 0 8 0.5 Oral pain 4 14 0.5 6 0 Vomiting 11 0 3 0 Investigations Weight loss 49 6 14 1 General disorders and administration site conditions Fatigue 41 5 20 1 Asthenia 12 0 7 0 Pyrexia 11 1 5 0 Vascular disorders Hypertension 6 41 10 12 2 Metabolism and nutrition disorders Decreased appetite 30 2 5 0 Nervous system disorders Headache 17 0 6 0 Dysgeusia 6 0 0 0 Musculoskeletal and connective tissue disorders Pain in extremity 15 1 7 0 Muscle spasms 10 0 3 0 Respiratory, thoracic and mediastinal disorders Dysphonia 13 0.5 3 0 Epistaxis 7 0 1 0 Neoplasms benign, malignant and unspecified Squamous cell carcinoma of skin 3 3 0 0 1 National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 2 Includes the following terms: abdominal pain, abdominal discomfort, hepatic pain, esophageal pain, esophageal discomfort, abdominal pain lower, abdominal pain upper, abdominal tenderness, abdominal rigidity 3 Includes the following terms: stomatitis, aphthous stomatitis, mouth ulceration, mucosal inflammation 4 Includes the following terms: oral pain, oropharyngeal discomfort, glossitis, burning mouth syndrome, glossodynia 5 Palmar-plantar erythrodysesthesia syndrome (Hand-foot skin reaction) 6 Includes the following terms: hypertension, blood pressure increased, blood pressure systolic increased The relative increase for the following laboratory abnormalities observed in NEXAVAR-treated patients as compared to patients receiving placebo in the DECISION study is similar to that observed in the RCC and HCC studies: lipase, amylase, hypokalemia, hypophosphatemia, neutropenia, lymphopenia, anemia, and thrombocytopenia.
Hypocalcemia was more frequent and more severe in patients with DTC, especially those with a history of hypoparathyroidism, compared to patients with RCC or HCC. Other laboratory test abnormalities reported in DECISION are presented in Table 9 Table 9: Laboratory Test Abnormalities Reported in DECISION (DTC Laboratory Parameter 1 NEXAVAR N=207 Placebo N=209 All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Elevated ALT 59 4 24 0 Elevated AST 54 2 15 0 Hypocalcemia 36 10 11 3 1 Laboratory parameters graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0).
Additional Data from Multiple Clinical Trials The following additional drug-related adverse reactions and laboratory abnormalities were reported from clinical trials of NEXAVAR (very common 10% or greater, common 1 to less than 10%, uncommon 0.1% to less than 1%, rare less than 0.1 %): Cardiovascular: Common: congestive heart failure* †, myocardial ischemia and/or infarction Uncommon: hypertensive crisis* Rare: QT prolongation* Dermatologic: Very common: erythema Common: exfoliative dermatitis, acne, flushing, folliculitis, hyperkeratosis Uncommon: eczema, erythema multiforme Digestive: Very common: increased lipase, increased amylase Common: mucositis, stomatitis (including dry mouth and glossodynia), dyspepsia, dysphagia, gastrointestinal reflux Uncommon: pancreatitis, gastritis, gastrointestinal perforations*, cholecystitis, cholangitis Note that elevations in lipase are very common (41%, see below); a diagnosis of pancreatitis should not be made solely on the basis of abnormal laboratory values General Disorders: Very common: infection, hemorrhage (including gastrointestinal* and respiratory tract* and uncommon cases of cerebral hemorrhage*), asthenia, pain (including mouth, bone, and tumor pain), pyrexia, decreased appetite Common: influenza-like illness Hematologic: Very common: leukopenia, lymphopenia Common: anemia, neutropenia, thrombocytopenia Uncommon: INR abnormal Hepatobiliary disorders: Rare: drug-induced liver injury (including hepatic failure and death) Hypersensitivity: Uncommon: hypersensitivity reactions (including skin reactions and urticaria), anaphylactic reaction Metabolic and Nutritional: Very common: hypophosphatemia Common: transient increases in transaminases, hypocalcemia, hypokalemia, hyponatremia, hypothyroidism Uncommon: dehydration, transient increases in alkaline phosphatase, increased bilirubin (including jaundice), hyperthyroidism Musculoskeletal: Very common: arthralgia Common: myalgia, muscle spasms Nervous System and Psychiatric: Common: depression, dysgeusia Uncommon: tinnitus, reversible posterior leukoencephalopathy* Renal and Genitourinary: Common: renal failure, proteinuria Rare: nephrotic syndrome Reproductive: Common: erectile dysfunction Uncommon: gynecomastia Respiratory: Common: rhinorrhea Uncommon: interstitial lung disease-like events (includes reports of pneumonitis, radiation pneumonitis, acute respiratory distress, interstitial pneumonia, pulmonitis and lung inflammation) In addition, the following medically significant adverse reactions were uncommon during clinical trials of NEXAVAR: transient ischemic attack, arrhythmia, and thromboembolism. For these adverse reactions, the causal relationship to NEXAVAR has not been established. *adverse reactions may have a life-threatening or fatal outcome. † reported in 1.9% of patients treated with NEXAVAR (N= 2276).
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of NEXAVAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic disorders: Thrombotic microangiopathy (TMA) Dermatologic: Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) Hypersensitivity: Angioedema Musculoskeletal: Rhabdomyolysis, osteonecrosis of the jaw Respiratory: Interstitial lung disease-like events (which may have a life-threatening or fatal outcome) Vascular: Arterial (including aortic) aneurysms, dissections, and rupture
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction1 | NEXAVARN=297 | PlaceboN=302 | ||||
| All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % | |
| Any Adverse Reaction | 98 | 39 | 6 | 96 | 24 | 8 |
| Gastrointestinal | ||||||
| Diarrhea | 55 | 10 | <1 | 25 | 2 | 0 |
| Anorexia | 29 | 3 | 0 | 18 | 3 | <1 |
| Nausea | 24 | 1 | 0 | 20 | 3 | 0 |
| Vomiting | 15 | 2 | 0 | 11 | 2 | 0 |
| Constipation | 14 | 0 | 0 | 10 | 0 | 0 |
| Constitutional symptoms | ||||||
| Fatigue | 46 | 9 | 1 | 45 | 12 | 2 |
| Weight loss | 30 | 2 | 0 | 10 | 1 | 0 |
| Pain | ||||||
| Pain, abdomen | 31 | 9 | 0 | 26 | 5 | 1 |
| Dermatology/skin | ||||||
| Hand-foot skin reaction | 21 | 8 | 0 | 3 | <1 | 0 |
| Rash/desquamation | 19 | 1 | 0 | 14 | 0 | 0 |
| Alopecia | 14 | 0 | 0 | 2 | 0 | 0 |
| Pruritus | 14 | <1 | 0 | 11 | <1 | 0 |
| Dry skin | 10 | 0 | 0 | 6 | 0 | 0 |
| Hepatobiliary/pancreas | ||||||
| Liver dysfunction | 11 | 2 | 1 | 8 | 2 | 1 |
| Laboratory Parameter1 | NEXAVARN=297 | PlaceboN=302 | ||
| All Grades(%) | Grade 3 or 4 (%) | All Grades(%) | Grade 3 or 4 (%) | |
| Hypoalbuminemia | 59 | 0 | 47 | 0 |
| Elevated Lipase | 40 | 9 | 37 | 9 |
| Lymphopenia | 47 | NR | 42 | NR |
| 46 | 4 | 41 | <1 | |
| Elevated INR | 42 | 4 | 34 | 2 |
| Hypophosphatemia | 35 | 11 | 11 | 2 |
| Elevated Amylase | 34 | 2 | 29 | 2 |
| Hypocalcemia | 27 | 2.4 | 15 | 1 |
| Hypokalemia | 10 | <1 | 6 | <1 |
| Adverse Reaction1 | NEXAVARN=451 | PlaceboN=451 | ||||
| All Grades% | Grade 3% | Grade 4% | All Grades% | Grade 3% | Grade 4% | |
| Any Adverse Reactions | 95 | 31 | 7 | 86 | 22 | 6 |
| Gastrointestinal symptoms | ||||||
| Diarrhea | 43 | 2 | 0 | 13 | <1 | 0 |
| Nausea | 23 | <1 | 0 | 19 | <1 | 0 |
| Anorexia | 16 | <1 | 0 | 13 | 1 | 0 |
| Vomiting | 16 | <1 | 0 | 12 | 1 | 0 |
| Constipation | 15 | <1 | 0 | 11 | <1 | 0 |
| Dermatology/skin | ||||||
| Rash/desquamation | 40 | <1 | 0 | 16 | <1 | 0 |
| Hand-foot skin reaction | 30 | 6 | 0 | 7 | 0 | 0 |
| Alopecia | 27 | <1 | 0 | 3 | 0 | 0 |
| Pruritus | 19 | <1 | 0 | 6 | 0 | 0 |
| Dry skin | 11 | 0 | 0 | 4 | 0 | 0 |
| Constitutional symptoms | ||||||
| Fatigue | 37 | 5 | <1 | 28 | 3 | <1 |
| Weight loss | 10 | <1 | 0 | 6 | 0 | 0 |
| Cardiovascular, General | ||||||
| Hypertension | 17 | 3 | <1 | 2 | <1 | 0 |
| Hemorrhage/bleeding | ||||||
| Hemorrhage – all sites | 15 | 2 | 0 | 8 | 1 | <1 |
| Pulmonary | ||||||
| Dyspnea | 14 | 3 | <1 | 12 | 2 | <1 |
| Neurology | ||||||
| Neuropathy-sensory | 13 | <1 | 0 | 6 | <1 | 0 |
| Pain | ||||||
| Pain, abdomen | 11 | 2 | 0 | 9 | 2 | 0 |
| Pain, headache | 10 | <1 | 0 | 6 | <1 | 0 |
| Pain, joint | 10 | 2 | 0 | 6 | <1 | 0 |
| Laboratory Parameter1 | NEXAVARN=451 | PlaceboN=451 | ||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Hypophosphatemia | 45 | 13 | 11 | 3 |
| Anemia | 44 | 2 | 49 | 4 |
| Elevated Lipase | 41 | 12 | 30 | 7 |
| Elevated Amylase | 30 | 1 | 23 | 3 |
| Lymphopenia | 23 | 13 | 13 | 7 |
| Neutropenia | 18 | 5 | 10 | 2 |
| 12 | 1 | 5 | 0 | |
| Hypocalcemia | 12 | 2 | 8 | <1 |
| Hypokalemia | 5 | 1 | <1 | <1 |
| Adverse Reaction | NEXAVAR N = 207 | Placebo N = 209 | |||
|---|---|---|---|---|---|
| All Grades (%) | Grades 3 and 4 (%) | All Grades (%) | Grades 3 and 4 (%) | ||
| Skin and subcutaneous tissue disorders | |||||
| PPES5 | 69 | 19 | 8 | 0 | |
| Alopecia | 67 | 0 | 8 | 0 | |
| Rash | 35 | 5 | 7 | 0 | |
| Pruritus | 20 | 0.5 | 11 | 0 | |
| Dry skin | 13 | 0.5 | 5 | 0 | |
| Erythema | 10 | 0 | 0.5 | 0 | |
| Hyperkeratosis | 7 | 0 | 0 | 0 | |
| Gastrointestinal disorders | |||||
| Diarrhea | 68 | 6 | 15 | 1 | |
| Stomatitis3 | 24 | 2 | 3 | 0 | |
| Nausea | 21 | 0 | 12 | 0 | |
| Abdominal pain2 | 20 | 1 | 7 | 1 | |
| Constipation | 16 | 0 | 8 | 0.5 | |
| Oral pain4 | 14 | 0.5 | 6 | 0 | |
| Vomiting | 11 | 0 | 3 | 0 | |
| Investigations | |||||
| Weight loss | 49 | 6 | 14 | 1 | |
| General disorders and administration site conditions | |||||
| Fatigue | 41 | 5 | 20 | 1 | |
| Asthenia | 12 | 0 | 7 | 0 | |
| Pyrexia | 11 | 1 | 5 | 0 | |
| Vascular disorders | |||||
| Hypertension6 | 41 | 10 | 12 | 2 | |
| Metabolism and nutrition disorders | |||||
| Decreased appetite | 30 | 2 | 5 | 0 | |
| Nervous system disorders | |||||
| Headache | 17 | 0 | 6 | 0 | |
| Dysgeusia | 6 | 0 | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | |||||
| Pain in extremity | 15 | 1 | 7 | 0 | |
| Muscle spasms | 10 | 0 | 3 | 0 | |
| Respiratory, thoracic and mediastinal disorders | |||||
| Dysphonia | 13 | 0.5 | 3 | 0 | |
| Epistaxis | 7 | 0 | 1 | 0 | |
| Neoplasms benign, malignant and unspecified | |||||
| Squamous cell carcinoma of skin | 3 | 3 | 0 | 0 | |
| Laboratory Parameter1 | NEXAVARN=207 | PlaceboN=209 | ||
| All Grades(%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Elevated ALT | 59 | 4 | 24 | 0 |
| Elevated AST | 54 | 2 | 15 | 0 |
| Hypocalcemia | 36 | 10 | 11 | 3 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], NEXAVAR may cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform a drug-associated risk. In animal reproduction studies, oral administration of sorafenib to pregnant rats and rabbits during the period of organogenesis resulted in embryo-fetal toxicities at maternal exposures that were significantly lower than human exposures at the recommended dose of 400 mg twice daily (see Data).
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data In animal reproduction studies, sorafenib was teratogenic and induced embryo-fetal toxicity (including increased post-implantation loss, resorptions, skeletal retardations, and retarded fetal weight) when administered orally to pregnant rats and rabbits during the period of organogenesis. The effects occurred at doses considerably below the recommended human dose of 400 mg twice daily (approximately 500 mg/m 2 /day on a body surface area basis).
Adverse intrauterine development effects were seen at doses >0.2 .mg/kg/day (1.2 mg/m 2 /day) in rats and ≥0.3 mg/kg/day (≥3.6 mg/m 2 /day) in rabbits. These doses result in exposures (AUC) that are approximately 0.008 times the AUC in patients at the recommended dose.
Mechanism of action
12.1 Mechanism of Action Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis.
Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Cardiac Electrophysiology The effect of NEXAVAR 400 mg twice daily on the QTc interval was evaluated in a multi-center, open-label, non-randomized trial in 53 patients with advanced cancer. No large changes in the mean QTc intervals (that is, >20 ms) from baseline were detected in the trial. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2 [see Warnings and Precautions (5.9), Drug Interactions (7.3)].
Pharmacokinetics
Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours.
Excretion Sorafenib accounted for approximately 70–85% of the circulating analytes in plasma at steady-state.
Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces and 19% of the dose excreted in urine as glucuronidated metabolites.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Multiple doses of NEXAVAR for 7 days resulted in a 2.5- to 7-fold accumulation compared to a single dose. Steady-state plasma sorafenib concentrations were achieved within 7 days, with a peak-to-trough ratio of mean concentrations of less than 2. The steady-state concentrations of sorafenib following administration of NEXAVAR 400 mg twice daily were evaluated in DTC, RCC and HCC patients.
Patients with DTC have mean steady-state concentrations that are 1.8-fold higher than patients with HCC and 2.3-fold higher than those with RCC. The reason for increased sorafenib concentrations in DTC patients is unknown. Mean C max and AUC increased less than proportionally beyond oral doses of 400 mg administered twice daily.
Absorption After administration of NEXAVAR tablets, the mean relative bioavailability was 38–49% when compared to an oral solution. Following oral administration, sorafenib reached peak plasma levels in approximately 3 hours. Effects of Food With a moderate-fat meal (30% fat; 700 calories), bioavailability was similar to that in the fasted state.
With a high-fat meal (50% fat; 900 calories), bioavailability was reduced by 29% compared to that in the fasted state. Distribution In vitro binding of sorafenib to human plasma proteins was 99.5%. Elimination The mean elimination half-life of sorafenib was approximately 25 to 48 hours. Metabolism Sorafenib undergoes oxidative metabolism by hepatic CYP3A4, as well as glucuronidation by UGT1A9.
Excretion Sorafenib accounted for approximately 70–85% of the circulating analytes in plasma at steady-state. Eight metabolites of sorafenib have been identified, of which 5 have been detected in plasma. The main circulating metabolite of sorafenib, the pyridine N-oxide that comprises approximately 9–16% of circulating analytes at steady-state, showed in vitro potency similar to that of sorafenib.
Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces and 19% of the dose excreted in urine as glucuronidated metabolites. Unchanged sorafenib, accounting for 51% of the dose, was found in feces but not in urine.
Specific Populations A study of the pharmacokinetics of sorafenib indicated that the mean AUC of sorafenib in Asians (N=78) was 30% lower than in Whites (N=40). Sex and age do not have a clinically meaningful effect on the pharmacokinetics of sorafenib. Patients with Renal Impairment Mild (CLcr 50-80 mL/min), moderate (CLcr 30 - <50 mL/min), and severe (CLcr <30 mL/min) renal impairment do not affect the pharmacokinetics of sorafenib [see Use in Specific Populations (8.6)].
Patients with Hepatic Impairment Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment do not affect the pharmacokinetics of sorafenib [see Use in Specific Populations (8.7)]. Drug Interactions Studies Effect of Strong CYP3A4 Inhibitors on Sorafenib: Ketoconazole, a strong inhibitor of CYP3A4 and P-glycoprotein, administered at a dose of 400 not alter the mean AUC of a single oral dose of NEXAVAR 50 mg in healthy subjects.
Effect of Strong CYP3A4 Inducers on Sorafenib: Concomitant use of NEXAVAR with rifampin administered at a dose of 600 mg once daily for 5 days with a single oral dose of NEXAVAR 400 mg in healthy volunteers resulted in a 37% decrease in the mean AUC of sorafenib. Effect of Neomycin on Sorafenib: Neomycin administered as an oral dose of 1 g three times daily for 5 days decreased the mean AUC of sorafenib by 54% in healthy subjects administered a single oral dose of NEXAVAR 400 mg.
Effect of Sorafenib on Other Drugs: NEXAVAR 400 mg twice daily for 28 days did not increase the systemic exposure of concomitantly administered midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), and omeprazole (CYP2C19 substrate) [see Clinical Pharmacology (12.3)]. Drugs that Increase Gastric pH: The aqueous solubility of sorafenib is pH dependent, with higher pH resulting in lower solubility.
However, omeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 5 days, did not result in a clinically meaningful change in sorafenib single dose exposure. In Vitro Studies Sorafenib competitively inhibited CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in vitro. However, NEXAVAR 400 mg twice daily for 28 days with substrates of CYP3A4, CYP2D6 and CYP2C19 did not increase the systemic exposure of these substrates [see Drug Interactions (7.3)].
Sorafenib did not increase CYP1A2 and CYP3A4 activities, suggesting that sorafenib is unlikely to induce CYP1A2 or CYP3A4 in humans. Sorafenib inhibits glucuronidation by UGT1A1 and UGT1A9 in vitro. NEXAVAR could increase the systemic exposure of concomitantly administered drugs that are UGT1A1 or UGT1A9 substrates. Sorafenib inhibited P-glycoprotein in vitro.
NEXAVAR could increase the concentrations of concomitantly administered drugs that are P-glycoprotein substrates.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Nexavar · Bayer HealthCare Pharmaceuticals Inc. [US FDA-approved label, version 40, August 28, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .